Open Orphan plc changed its name to hVIVO plc on 26 October 2022, learn more here.

Investors

Open Orphan plc has changed its name to hVIVO plc (Ticker: HVO)

Watch hVIVO’s Capital Markets Day 2022 presentation here.

hVIVO is a publicly traded company on the London AIM and Euronext Growth stock exchanges under the symbol HVO

Yamin 'Mo' Khan

CEO at hVIVO

We are the world leader in testing infectious and respiratory disease vaccines and therapeutics using human challenge clinical trials. We provide end-to-end services to our diverse portfolio of clients, including four of the top 10 global biopharma companies. I look forward to driving further growth across the business this year and converting this substantial progress into value for our shareholders.

Regulatory News

Reasons to Invest

Rapidly Growing
Specialist CRO

£0M
£50.7M
2022 Revenue
c.0%
17.9%
2022 EBITDA Margin
£0M
£28.4M
Cash at year end
31 December 2022

Leader in Human
Challenge Trials

0 +
70 +
Completed Human
Challenge Studies
0 +
11 +
Challenge Study
Models
0 +
4000 +
Volunteers inoculated

Operational
Excellence

0
413
Volunteers Inoculated 
2022
£5-10M
Typical study size
0%
100%
Trial recruitment success

Well Positioned
for Growth

£0M
£76M
Contracted Orderbook
at 31 Dec 2022
c.£0M
£55M
FY23 Forecast
Revenue
0%
Mid-high teens
FY23 Target EBITDA Margin

Company at a Glance

Deep Roots
Dating back to 1946 with the UK Common Cold Unit
50+ Years
Combined service
Working with 4/10
Top Global Biopharma Companies
Industry Leading Safety
Record Across 70+ Challenge Trials
First Global
SARS-CoV2 Human Challenge Trial
FluCamp Volunteer Recruitment
Tech-enabled Generic Screening Recruitment Platform

Capital Markets Day – November 2022

02 Nov 2022
Capital Markets Day

Latest Presentation Deck

April 2023
Full Year Results Presentation
Download

Latest Investor Presentation

See more
Meet our experienced executive management team
Meet the team
AIM Rule 26

Combined Services

hVIVO Capability
Venn Life Sciences Capability
CMC
Preclinical
Phase I
Challenge
Study
Lab Services
Phase II
Biometrics
Regulatory
Venn Breda
Venn Paris
Biobank
Manchester
Dublin
Plumbers Row
Whitechapel Hotel
QMB
hVIVO's Location
Venn Location

End-To-End Early Clinical Development Services

hVIVO
Venn Life Sciences
FluCamp
Syringe inserted into medicine bottle

hVIVO is the world leader in testing infectious and respiratory disease products using human challenge study models

Learn more
Two lab technicians inspecting test tubes

Venn Life Sciences is an Integrated Drug Development partner offering a unique combination of drug development consultancy, clinical trial design and execution.

Visit Venn Life
Healthcare worker speaking with a clinical trial volunteer
FluCamp logo

FluCamp welcome volunteers to take part in our clinical trials under expertly supervised conditions.

Visit FluCamp

Interested in investing in hVIVO?
Contact our Investor Relations team.

IR@hVIVO.com
chevron-downcross-circle